Evaluatepharma latest release of the 2017 global pharmaceutical industry forward -looking report，The following points are worthy of attention:

 

  ● Pfizer still firmly occupies the status of the boss of the pharmaceutical industry，In 2017, the sales of its global prescription drugs and OTC are expected to be close to $ 50 billion;

 

  ● Ada Mu Ming (Humira) is still the best -selling drug in the world;

 

  ● Roche (Roche) and Sanofi eagerly waiting for their key products to be approved，Among them, Roche is multiple sclerosis treatment drugs OCREVUS，Sanofi is Dupilumab, a drug treatment drug;

 

  ● Eli Lilly, Cialis and Pfizer Viagra, will face the biggest threat;

 

  ● Possible tax reforms and corresponding capital cashbacks or giant mergers and acquisitions;

 

  ● cutting-edge technology stake sports betting appsuch My stake betting appas CAR-T therapy、CRISPR gene editing technology and gene therapy progress。

 

  Let's focus on the situation of the top ten best -selling medicines and top ten pharmaceutical companies in 2017。

 

  Bio -similar medicine threatened 7 best -selling medicines

 

  According to the prediction，2017 global best -selling medicine TOP 10 list is not & ldquo; black horse & rdquo; appear。Admud Mutteru's annual sales of $ 17.6 billion still ranked first，For many pharmaceutical companies，It must rely on its overall product line to reach this huge value。but，ABBVIE's & ldquo; good days & rdquo;，It is expected to be listed in 2018 as soon as possible。The power of biological similar medicines is not only here，Among the top ten best -selling medicines in the world in 2017, 6 other products will also be threatened by competition。

 

 

  but，Revlimid is still strong，This medicine is the growth pillar of Celgene (Celgene) in recent years，and will continue。stake betting appstake sports betting appForecast，The annual sales of the drug in 2017 were $ 8.1 billion，In another report，Evaluatepharma predicts its sales in 2022 will reach $ 13 billion。Pfizer's PREVNAR 13 also enjoyed a long patent protection period，Its annual sales in 2017 are expected to be $ 6 billion。This result seems bland，A very important reason is that it defeated himself: Peer quickly covered the market，So I did not leave much gap to be filled。

 

  Geely is not worried & ldquo;

 

  Of course，Best -selling medicine may not necessarily have to encounter a sharp decline in sales after the patent expires。In the cooled hepatitis C drug market，Harvoni of Gilead Sciences unfortunately became one of the members。stake betting appstake sports betting appForecast，The annual sales of the drug in 2017 will drop from nearly 10 billion US dollars this year to $ 7 billion。Geilide's entire hepatitis C drug product portfolio，Including new drug EPCLUSA for all genotypes C，It is expected that it can only bring $ 11.7 billion in sales。

 

  EvaluatePharma described this as & ldquo; the collapse of the dynasty & rdquo;。This year，Geilide's entire hepatitis C drug product portfolio is expected to contribute 14.9 billion US dollars，More than $ 11.2 billion in the annual income target of Xinji Medicine。Current，Geely is under great pressure to fill the loss of sales，Investors are not satisfied with the current situation。Perhaps，Various measures that Geely's saving their income will make it a headlines in 2017。

 

  The voices of Geely's big mergers and acquisitions are extremely high。Facts，It has plenty of cash at hand，Overseas assets are more than $ 16 billion，Ruo Trump administration implements the new tax policy，This money is expected to return to the United States。but，Once all American pharmaceutical companies can bring offshore cash home at a very small price,，Perhaps it will promote the significant increase in the purchase price。

 

  Then turn the eyes back to the threat of biological drugs。Byebila and Boehringer Ingelheim's biological drug (planned to be listed in the United States this month)，Lantus of Sanofi fell directly to the end of the global best -selling medicine TOP 10 in 2017，Predated annual sales fell from US $ 6.9 billion in 2016 to $ 5.2 billion in 2017。In addition，Pfizer's biological similar medicine for REMICADE approved My stake betting appby stake online sports bettingPfizer，Also Johnson & Johnson) It is expected to be placed in risks in risks。

 

  At the same time，Enbrel's biosimination of ENBREL (Sandoz) under the Nuohua Sandoz has obtained FDA approval，Danjin (AMGEN) is still obstructing it through the patent court。In addition，Roche's three best -selling products Rituxan、Bergumab and Herceptin will be ranked among the 3 3 of the 2017 global best -selling drug TOP 10 list.、4、6 digits，It will face the competition of similar biological drugs in the next few years。

 

  Step squeezed AZ into the new face of the top ten list

 

  but，Although the US pharmaceutical industry will face great changes at the policy level (such as replacing the FDA director，The "21st Century healing Act" accelerated drug development just passed，The new government may take management and control measures for drug prices)，The ranking pattern of global pharmaceutical companies will not change greatly in a short time，Unless there are super mergers and acquisitions。

 

 

  Pfizer's status is still unshakable，It is expected that the sales of prescriptions and OTC in 2017 will reach $ 49.9 billion，Some of them have to be attributed to its mergers and acquisitions of Hospira。Novartis and Roche will go side by side，Board 2、3 digits，The sales of prescriptions and OTC in 2017 are expected to be $ 42.5 billion。

 

  Sanofer、Merhado、Glaxosmithkline (GLAXOSMITHKLINE) occupy the midstream position of the global pharmaceutical company TOP 10， The revenue range predicted in 2017 is 31.2 billion US dollars (GSK) ~ 39.9 billion US dollars (Sanofi)。Abbvie、Geely and the generic Stake Sports Bettingdrug stake sports betting appgiant TEVA (TEVA) divide the remaining seats in the list，Its revenue in 2017 is expected to be more than $ 20 billion。It is worth mentioning that，Bevava is the new face of the list，In the report last year，The company in its position is Astrazeneca。